IN8bio Announces Preclinical Data from Gamma-Delta T Cell Engager Platform at AACR 2025

IN8BIO, INC.

INB-619 (CD19) and INB-633 (CD33) showed potent dose-related killing of leukemia cells at low picomolar concentrations in preclinical studies.
Platform activated and expanded both Vδ1+ and Vδ2+ T cell subsets, addressing reduced cell counts in cancer patients.
Minimal secretion of cytokines IL-6, IL-10, IL-17a suggests lower risk of cytokine release syndrome versus conventional CD3 TCEs.
CEO William Ho highlighted potential for off-the-shelf, scalable platform to target cancers and autoimmune diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.